Form 4: Dexcom EVP, Chief HR Officer Sells Over 6,000 Shares Under Pre-Arranged Trading Plan

Sadie Stern, Executive Vice President and Chief HR Officer of Dexcom Inc. (DXCM), reported the sale of 6,184 shares of common stock for approximately $526,300, executed under a Rule 10b5-1 trading plan.

Summary

• Sadie Stern, EVP, Chief HR Officer of Dexcom Inc. (DXCM), sold 6,184 shares of common stock on May 27, 2025.
• The shares were sold at a weighted average price of $85.1097 per share, with individual trades ranging from $84.75 to $85.445.
• The total value of the shares sold amounts to approximately $526,300.
• This transaction was conducted pursuant to a Rule 10b5-1 trading plan adopted by Ms. Stern on February 20, 2025, designed for the orderly disposition of her shares.
• Following this transaction, Ms. Stern beneficially owns 109,621 shares of Dexcom common stock.
• The remaining beneficial ownership includes 74,450 unvested restricted stock units (RSUs), with various vesting schedules extending through March 8, 2028.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it's an insider sale, the fact that it's conducted under a pre-arranged 10b5-1 plan mitigates concerns about opportunistic selling, indicating a planned financial management strategy rather than a reaction to negative company news.

Negatives

• An insider sale, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces the executive's direct equity stake in the company.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction, focusing solely on an insider stock transaction.

Management Comments

• "On February 20, 2025, Ms. Stern adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Stern. The shares set forth above were sold pursuant to the 10b5-1 Plan."
• "This transaction was executed in multiple trades at prices ranging from $84.75 to $85.445. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected."

Industry Context

This Form 4 filing reports a routine insider stock transaction and does not provide information relevant to broader industry trends or competitive landscape within the medical device or continuous glucose monitoring (CGM) sector.

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in insider ownership, which is generally expected under pre-arranged trading plans and is unlikely to significantly impact shareholder confidence given its planned nature.
• Employees: No direct impact on employees is indicated by this transaction.

Next Steps

• Continued vesting of Sadie Stern's remaining 74,450 unvested restricted stock units according to their respective schedules through March 8, 2028.

Key Dates

Keywords

Dexcom, DXCM, SEC Form 4, Insider Sale, 10b5-1 Plan, Executive Compensation, Stock Transaction, Sadie Stern, Medical Devices, Continuous Glucose Monitoring